1. O'Neill J. 2016. Tackling drug-resistant infections globally: final report and recommendations. Government of the United Kingdom;London: p. 10–17.
2. Rex JH, Pfaller MA. 2002; Has antifungal susceptibility testing come of age? Clin Infect Dis. 35:982–9. DOI:
10.1086/342384. PMID:
12355386.

3. Solomon SL, Oliver KB. 2014; Antibiotic resistance threats in the United States: stepping back from the brink. Am Fam Physician. 89:938–41. PMID:
25162160.
4. Ben-David D, Kordevani R, Keller N, Tal I, Marzel A, Gal-Mor O, et al. 2012; Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect. 18:54–60. DOI:
10.1111/j.1469-0691.2011.03478.x. PMID:
21722257.

5. Centers for Disease Control. 2009; Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. MMWR Morb Mortal Wkly Rep. 58:256–60. PMID:
19300408.
6. Lee E, Lee S, Yoon S, Lee Y. 2021; Number of cabapenem-resistant Enterobacteriaceae infections in Republic of Korea (2018-2020). Public Health Wkly Rep. 14:2765–72.
9. Papst L, Beović B, Pulcini C, Durante-Mangoni E, Rodríguez-Baño J, Kaye KS, et al. 2018; Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals. Clin Microbiol Infect. 24:1070–6. DOI:
10.1016/j.cmi.2018.01.015. PMID:
29410094.

10. Wi YM, Kang CI. 2018; Antimicrobial therapy for infections caused by carbapenem-resistant Gram-negative bacteria. Korean J Med. 93:439–46. DOI:
10.3904/kjm.2018.93.5.439.

12. Majewski P, Wieczorek P, Łapuć I, Ojdana D, Sieńko A, Sacha P, et al. 2017; Emergence of a multidrug-resistant Citrobacter freundii ST8 harboring an unusual VIM-4 gene cassette in Poland. Int J Infect Dis. 61:70–3. DOI:
10.1016/j.ijid.2017.05.016. PMID:
28602727.

13. Venditti C, Fortini D, Villa L, Vulcano A, D'Arezzo S, Capone A, et al. 2017; Circulation of blaKPC-3-carrying IncX3 plasmids among Citrobacter freundii isolates in an Italian hospital. Antimicrob Agents Chemother. 61:e00505–17. DOI:
10.1128/AAC.00505-17. PMID:
28559268. PMCID:
PMC5527586.
14. Lin MY, Lyles-Banks RD, Lolans K, Hines DW, Spear JB, Petrak R, et al. 2013; The importance of long-term acute care hospitals in the regional epidemiology of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae. Clin Infect Dis. 57:1246–52. DOI:
10.1093/cid/cit500. PMID:
23946222. PMCID:
PMC8383150.
15. Snitkin ES, Zelazny AM, Thomas PJ, Stock F, Henderson DK, Palmore TN, et al. 2012; Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-genome sequencing. Sci Transl Med. 4:148ra116. DOI:
10.1126/scitranslmed.3004129. PMID:
22914622. PMCID:
PMC3521604.

16. Kim JS, Jin YH, Park SH, Han S, Kim HS, Park JH, et al. 2019; Emergence of a multidrug-resistant clinical isolate of Escherichia coli ST8499 strain producing NDM-13 carbapenemase in the Republic of Korea. Diagn Microbiol Infect Dis. 94:410–2. DOI:
10.1016/j.diagmicrobio.2019.02.013. PMID:
30879710.

17. Clinical. 2011. Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement. Clinical and Laboratory Standards Institute;Wayne: p. 50. DOI:
10.1016/j.diagmicrobio.2019.02.013.
18. Wang Q, Wang X, Wang J, Ouyang P, Jin C, Wang R, et al. 2018; Phenotypic and genotypic characterization of carbapenem-resistant Enterobacteriaceae: data from a longitudinal large-scale CRE study in China (2012-2016). Clin Infect Dis. 67(suppl_2):S196–205. DOI:
10.1093/cid/ciy660. PMID:
30423057.
19. Arnold RS, Thom KA, Sharma S, Phillips M, Kristie Johnson J, Morgan DJ. 2011; Emergence of Klebsiella pneumoniae carbapenemase-producing bacteria. South Med J. 104:40–5. DOI:
10.1097/SMJ.0b013e3181fd7d5a. PMID:
21119555. PMCID:
PMC3075864.

20. Yan L, Sun J, Xu X, Huang S. 2020; Epidemiology and risk factors of rectal colonization of carbapenemase-producing Enterobacteriaceae among high-risk patients from ICU and HSCT wards in a university hospital. Antimicrob Resist Infect Control. 9:155. DOI:
10.1186/s13756-020-00816-4. PMID:
32967718. PMCID:
PMC7513325.

21. Tamma PD, Goodman KE, Harris AD, Tekle T, Roberts A, Taiwo A, et al. 2017; Comparing the outcomes of patients with carbapenemase-producing and non-carbapenemase-producing carbapenem-resistant Enterobacteriaceae bacteremia. Clin Infect Dis. 64:257–64. DOI:
10.1093/cid/ciw741. PMID:
28013264. PMCID:
PMC5241781.
22. Hussein K, Raz-Pasteur A, Finkelstein R, Neuberger A, Shachor-Meyouhas Y, Oren I, et al. 2013; Impact of carbapenem resistance on the outcome of patients' hospital-acquired bacteraemia caused by Klebsiella pneumoniae. J Hosp Infect. 83:307–13. DOI:
10.1016/j.jhin.2012.10.012. PMID:
23313086.

23. Toth DJA, Khader K, Slayton RB, Kallen AJ, Gundlapalli AV, O'Hagan JJ, et al. 2017; The potential for interventions in a long-term acute care hospital to reduce transmission of carbapenem-resistant Enterobacteriaceae in affiliated healthcare facilities. Clin Infect Dis. 65:581–7. DOI:
10.1093/cid/cix370. PMID:
28472233.

24. Ben-David D, Masarwa S, Fallach N, Temkin E, Solter E, Carmeli Y, et al. 2019; Success of a national intervention in controlling carbapenem-resistant Enterobacteriaceae in Israel's long-term care facilities. Clin Infect Dis. 68:964–71. DOI:
10.1093/cid/ciy572. PMID:
29986007.
